The Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has filed a Form 8.3 disclosure with the Irish Takeover Panel concerning its interests in Avadel Pharmaceuticals plc. As per the filing dated February 4, 2026, Vanguard holds a 5.94% interest in Avadel, amounting to 5,788,891 ordinary shares. The disclosure ensures compliance with Rule 8.3 of the Irish Takeover Panel Act, 1997, necessary for parties holding 1% or more in relevant securities during a takeover bid.

The disclosure also encompasses trading activity, noting purchases of 1,421 shares at $21.58 per share and sales of 2,336 shares at the same price. No dealings, agreements, or derivatives relevant to further transactions are reported. The documentation confirms no indemnity or option arrangements are in place related to these securities.